Amneal Pharmaceuticals, Inc. AMRX Affordable Medicines — Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherResearchAndDevelopmentExpense.
The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amneal Pharmaceuticals, Inc.'s affordable medicines — other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amneal Pharmaceuticals, Inc.'s affordable medicines — other?
- Amneal Pharmaceuticals, Inc. (AMRX) reported affordable medicines — other of $6.14M in Q1 2026.
- How has Amneal Pharmaceuticals, Inc.'s affordable medicines — other changed year-over-year?
- Amneal Pharmaceuticals, Inc.'s affordable medicines — other decreased by 13.5% year-over-year, from $7.1M to $6.14M.
- What is the long-term trend for Amneal Pharmaceuticals, Inc.'s affordable medicines — other?
- Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s affordable medicines — other has grown at a -9.3% compound annual growth rate (CAGR), from $38.1M to $28.41M.
- What does affordable medicines — other mean?
- Aggregates miscellaneous operating expenses that are not captured in specific line items but are necessary for segment operations. This category helps in understanding the total operational overhead and identifying hidden cost drivers.